Please assess the completion status of the following clinical trial:

Trial Title: A Sub-study to LMF237A2302 to Assess the Effect of 24 Weeks Treatment With Initial Combination of Vildagliptin Plus Metformin

Study Design Characteristics:
- Allocation: None
- Intervention Model: SINGLE_GROUP
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: NONE
- Phase: PHASE3
- Number of Arms: 1.0

Eligibility Criteria:
Inclusion Criteria:~* Male or female (non-fertile or of childbearing potential using a medically approved birth control method) patients with type 2 diabetes~* Diagnosis of type 2 diabetes for at least 4 weeks prior to study entry~* Body mass index 22-40 kg/meter squared~* HbA1c \> 11% and/or FPG \>270 mg/dL~Exclusion Criteria:~* Pregnant or lactating female~* History of type 1 diabetes~* Evidence of significant diabetic complications~* Treatment with insulin or any other oral antidiabetic agent~Other protocol-defined inclusion/exclusion criteria may apply.

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: 78 Years
- Healthy Volunteers: f

Study Arms:
- vildagliptin + metformin (Type: EXPERIMENTAL): None

Based on this trial design, predict the completion outcome and termination type (if applicable).